Octagon Capital Advisors LP Chinook Therapeutics, Inc. Transaction History

Octagon Capital Advisors LP

  • $414 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
BUY
$12.59 - $18.8 $15.1 Million - $22.5 Million
1,195,453 Added 88.14%
2,551,703 $44.6 Million
Q1 2022

May 16, 2022
BUY
$12.02 - $16.69 $10.3 Million - $14.3 Million
856,250 Added 171.25%
1,356,250 $22.2 Million
Q4 2021

Feb 14, 2022
BUY
$10.69 - $16.83 $5.35 Million - $8.42 Million
500,000 New
500,000 $8.16 Million

Others Institutions Holding KDNY

# of Institutions
5
Shares Held
234K
Call Options Held
0
Put Options Held
0
View Full List

About CHINOOK THERAPEUTICS, INC.

KDNY Quotes by TradingView
  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email